US 10,799,578 B2 · Vaccine against porcine parvovirus

Abstract

The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

Claims22

Dependent claims

A porcine parvovirus (PPV) subunit vaccine comprising:

an effective amount of a PPV viral protein 2 (VP2) antigen comprising an isoleucine residue at amino acid position 25, a serine residue at amino acid position 36, an isoleucine residue at amino acid position 37, a glutamic acid residue or a glutamate residue at amino acid position 228, a serine residue at amino acid position 414, a glutamine residue at amino acid position 419, and a threonine residue at amino acid position 436,
wherein amino acid position numbering refers to an amino acid sequence of wild type PPV VP2.

Dependencies are inferred from the claim text.

Facts

Application

16/598,110Filed 10 Oct 2019 · continuation

Priority

EP 161970913 Nov 2016

Published

US 2020/0030438 A130 Jan 2020

Granted

13 Oct 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 39/23
Viral antigens: parvoviridae, e.g. feline panleukopenia virus
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61P 31/20
Antivirals: for DNA viruses
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses

Family

Application15/801,730Parent of this continuation · filed 2 Nov 2017

US 2020/0030438 A1Pre-grant publication · published 30 Jan 2020

US 10,485,866 B2Parent of this continuation

US 2018/0133309 A1Published application

US 10,799,578 B2This patent

From the US filing history. Foreign family members aren’t listed.

Vaccine against porcine parvovirus

Life of this patent

Vaccine against porcine parvovirus

Life of this patent

Abstract

Claims22